The goal of this clinical trial is to investigate how well nicotine pouches and nicotine mini lozenges serve as substitutes for cigarettes when people try to switch from smoking to using these alternate nicotine products.
Participants will:
* Use nicotine pouches, nicotine mini lozenges, or no study product for a week and then try not to smoke for 3 weeks.
* Have 6 in-person research visits and 1 follow-up call
* Complete questionnaires at each study contact and use a smartphone app to record smoking and study product use

Start Date01 May 2025

Sponsor / Collaborator

University of Wisconsin Madison

[+1]

NCT06334016 / Not yet recruitingEarly Phase 1IIT

Acute Effects of Sequential Nicotine Vaping on the Pharmacokinetic and Pharmacodynamic Properties of Vaped THC: A Double-Blind, Placebo-Controlled, Randomized Within-Subject Crossover Study

This clinical trial assesses differences in the delivery of THC to the bloodstream depending on whether nicotine vapes are used before or after THC. While there has been much recent publicity about vaping products and concern about their safety considering their increasing use for THC administration, the THC delivery profile associated with THC liquid vaping products in human subjects is currently unknown. Importantly, how the delivery to the bloodstream of THC vaping liquids compare to delivery from smoked cannabis, which is the most used method of cannabis delivery, will serve as an important benchmark for evaluating the delivery and effects of THC vaping products, and their relative safety.

Start Date27 Mar 2025

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

[+1]

NCT06315881 / Not yet recruitingPhase 2IIT

Informing Oral Nicotine Pouch Regulations to Promote Public Health

This clinical trial evaluates the characteristics of oral nicotine pouches (ONPs) to determine if they are a comparable substitute to cigarette or smokeless tobacco (ST) products. ONPs contain nicotine but no tobacco and are used primarily by adult tobacco uses in the United States (US). ONPs are recognized by the Food and Drug Administration as having lower risk than combustible cigarettes and are approved as a modified risk tobacco product. While ONPs have lower toxic risk than other tobacco products, acute and longer term harm related to their use has not been studied. Information gathered from this study may identify product characteristics of ONPs that improve successful switching from high-risk cigarettes or ST to lower risk ONPs.

Start Date01 Dec 2024

Sponsor / Collaborator

Ohio State University Comprehensive Cancer Center

[+1]

100 Clinical Results associated with Nicotine

100 Translational Medicine associated with Nicotine

100 Patents (Medical) associated with Nicotine

29,234

Literatures (Medical) associated with Nicotine

01 Jan 2025·ADDICTIVE BEHAVIORS

Use of cannabis among youth who vape nicotine

Article

Author: Morean, Meghan E ; Bold, Krysten W ; Krishnan-Sarin, Suchitra ; Davis, Danielle R. ; Bold, Krysten W. ; Wu, Ran ; Morean, Meghan E. ; Davis, Danielle R ; Kong, Grace

BACKGROUND:

Youth e-cigarette use remains a public health concern and many youth want to quit. However, cannabis use is common among youth who use e-cigarettes, which may interfere with nicotine cessation efforts. This study aimed to investigate cannabis use among youth who vape nicotine and are motivated to quit nicotine.

METHODS:

Connecticut youth (N=223, M_age = 17.3 [SD=1.7] years) who completed an intake for a vaping cessation study reported on their nicotine vaping, cannabis products used, reasons for use, frequency of use, and readiness to quit cannabis. Descriptives characterized population. Regressions were used to examine association of cannabis use and nicotine vaping.

RESULTS:

Most reported cannabis use (lifetime: 92.4 %; past-month: 68.6 %). Cannabis smoking and vaping were highly prevalent (smoking: lifetime - 90.8 %, current - 63.6 %; vaping: lifetime - 90.8 %, current - 63.1 %). Most reported preferring smoking cannabis (58.7 %) over other routes of administration. Common reasons for cannabis use, were psychoactive (e.g., getting high), physical (e.g., improving sleep), and social (e.g., partying). Cannabis use frequency and preferring smoking cannabis (vs. other modes) was positively associated with more frequent nicotine vaping (ps < 0.05). Participants averaged 6.3 (of 10) on a readiness to quit cannabis scale, a moderate desire to quit.

CONCLUSIONS:

Cannabis use across multiple routes of administration was common among youth seeking help quitting vaping nicotine. Heaviness of cannabis and nicotine use appear to be associated, raising interesting harm-reduction challenges for those seeking to quit nicotine vaping. Understanding cannabis and nicotine co-use is important for targeting treatment for use of both substances.

01 Jan 2025·BEHAVIOURAL BRAIN RESEARCH

Central cholinergic transmission modulates endocannabinoid-induced marble-burying behavior in mice

Article

Author: Patel, Richa ; Rao, Laxmi ; Jain, Nishant Sudhir ; Patel, Chhatrapal ; Kesharwani, Anuradha

Central cholinergic system and endocannabinoid, anandamide exhibits anti-compulsive-like behavior in mice. However, the role of the central cholinergic system in the anandamide-induced anti-compulsive-like behavior is still unexplored. Therefore, the present study assessed the role of central cholinergic transmission in the anandamide-induced anti-compulsive activity using a marble-burying behavior (MBB) model in mice. The modulation in the anandamide-induced effect on MBB was evaluated using mice with altered central cholinergic transmission achieved by pretreatment (i.c.v.) with various cholinergic agents like acetylcholine (ACh), acetylcholinesterase inhibitor (AChEI), neostigmine, nicotine, mAChR antagonist, atropine, and nAChR antagonist, mecamylamine. The influence of anandamide treatment on the brain AChE activity was also evaluated. The results revealed that i.c.v. injection of anandamide (10, 20 µg/mouse, i.c.v.) dose-dependently reduced MBB in mice. Moreover, anandamide in all the tested doses inhibited the brain AChE activity indicating the role of an enhanced central cholinergic transmission in its anti-compulsive-like effect . Furthermore, the anti-compulsive-like effect of anandamide (20 µg/mouse, i.c.v.) was found to be enhanced in mice centrally pre-treated with, ACh (0.1 µg/mouse, i.c.v.) or AChEI, neostigmine (0.3 µg/mouse, i.c.v.). In addition, the anandamide-induced anti-compulsive-like effect was significantly increased in mice pre-treated with a low dose of nicotine (0.1 µg/mouse, i.c.v.) while, it was attenuated by the higher dose of nicotine (2 µg/mouse, i.c.v.). On the other hand, the anandamide (20 µg/mouse, i.c.v.) induced anti-compulsive-like effect was found to be diminished in mice pre-treated with mAChR antagonist, atropine (0.1, 0.5 µg/mouse, i.c.v.) and pre-injection of nAChR antagonist, mecamylamine (0.1, 0.5 µg/mouse, i.c.v.) potentiated the anandamide induced anti-compulsive-like response in mice. Thus, the present investigation delineates the modulatory role of an enhanced central cholinergic transmission in the anandamide-induced anti-compulsive-like behavior in mice by inhibition of brain AChE or via muscarinic and nicotinic receptors mediated mechanism.

01 Jan 2025·COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY

Biotransformation of carbamazepine and nicotine in juvenile American alligator (Alligator mississippiensis) in vitro hepatic S9 vs. in situ perfused liver

Article

Author: Petersen, Lene H ; Umeki, Yu ; Hala, David ; Petersen, Lene H.

American alligators (Alligator mississippiensis) are apex predators and sentinel species in the coastal wetland ecosystem along the Gulf of Mexico. There is concern for alligator exposure and susceptibility to chemical contaminants due to their high trophic level and lower metabolic capability. At present, their hepatic biotransformation capacity to metabolize or detoxify contaminants has not been comprehensively determined. In this study, the hepatic biotransformation capability of juvenile American alligators to metabolize two commonly found environmental pharmaceuticals: carbamazepine (CBZ) or nicotine (NCT) was evaluated. The formation of their respective primary metabolites, i.e., carbamazepine-10,11-epoxide (CBZ-E) and cotinine (CTN), was evaluated at 10 μM (within the human therapeutic range). The in vitro S9 and a novel in situ liver perfusion assays were used to characterize and compare metabolic ability in isolated hepatic enzymes vs. whole organ (liver). For CBZ, the perfused livers exhibited only 30% of intrinsic formation clearance (CL_f,int) relative to the S9 assay. The metabolism of NCT was not detectable in the S9 assay and was only observed in the perfused liver assay. Compared to the corresponding rat models (S9 or perfused livers),alligators' CL_f,int was 2060% for CBZ and 50% for NCT of rats. Additionally, NCT exposure increased lactate levels in perfused livers indicating metabolic stress. This study provides insight into the hepatic capability of alligators to metabolize CBZ and NCT using an established in vitro (S9) system and a newly developed in situ liver perfusion system.

144

News (Medical) associated with Nicotine

16 Oct 2024

·www.globenewswire.com

Firefly Neuroscience Collaborates with Bright Minds Biosciences to Analyze the Data from its Positive Phase 1 Study using its Artificial Intelligence, FDA-Cleared BNA™ Technology

During the Phase 1 study, subjects utilized EEG headsets provided by Firefly partner, Zeto, after which the data was analyzed using Firefly’s advanced AI BNA technology analysis platformTORONTO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced collaborating with Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders and refractory epilepsy, to analyze the data from its first-in-human Phase 1 study of its lead compound, BMB-101. The study demonstrated positive results of the qEEG (Quantitative Electroencephalogram) data. During the EEG recording, subjects were seated with a U.S. Food and Drug Administration (FDA)- approved 19 electrode EEG headset provided by Firefly strategic partner, Zeto™ Inc. Channels were sampled at 250 or 500 Hz and referenced to A1/A2 channels (linked-ears reference) during recording. The EEG recording time was 10 minutes (~5 minutes resting with eyes closed and ~5 minutes resting with eyes open). There were four EEG recording timepoints: day 1 pre-dose (immediately before dosing) and post-dose (1h after dosing), and day 7 pre-dose and post-dose. Data was analyzed using the FireFly Neuroscience advanced EEG analysis platform. “Our artificial intelligence platform has tremendous value for the advancement and insight of clinical studies,” said Jon Olsen, CEO of Firefly. “We are pleased to have successfully collaborated with Bright Minds to analyze the data of their phase 1 study and look forward to working closely with their team once again as well as other leading biotechnology companies.” “The positive topline findings from our recently completed Phase 1 study of BMB-101, together with the observations from the qEEG portion of the study, validate our approach, as we continue to evaluate this important product candidate. BMB-101 is clearly [getting into the brain/achieving brain penetration] and activating the target receptors as we had predicted, setting us up for potential success in a number of indications that have been validated with the 5-HT2C mechanism. With this study complete, BMB-101 is now a Phase 2 ready asset, and we intend to move forward with an investigative new drug submission immediately,” stated Ian McDonald, CEO of Bright Minds. About FireflyFirefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use. Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly’s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNA™, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician’s ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient’s outcome. Please visit https://fireflyneuro.com/ for more information. About BMB-101BMB-101, a highly selective 5-HT2C, Gq-protein biased agonist, has demonstrated compelling activity in a host of in vitro and in vivo nonclinical tests. Compared to Lorcaserin, BMB-101 exhibits strong Gq biased signaling, coupled with minimal beta-arrestin recruitment. Bright Minds believes that G-protein biased signaling translates to better tolerance profile for this second-generation 5-HT2C agonist, making BMB-101 a best-in-class 5-HT2C agonist. Mechanistically, Serotonin (5-Hydroxytryptamine, 5-HT) is a monoamine neurotransmitter widely expressed in the central nervous system, and drugs modulating 5-HT have made a major impact in mental health disorders. Central 5-HT systems have long been associated with the control of ingestive behaviors and the modulation of the behavioral effects of psychostimulants, opioids, alcohol, and nicotine. Results of clinical trials and animal studies indicate that 5-HT2C receptor agonists may have therapeutic potential in the treatment of addiction by decreasing the intake of opioids as well as impulsive behavior that can escalate compulsive drug use. BMB-101 is a new chemical entity (NCE) and constitutes a novel scaffold 5-HT2C agonist. 5-HT2C agonism is a well proven anticonvulsant mechanism. In translational animal models, BMB-101 demonstrated a significant reduction in both the number and intensity of epileptic seizures and is a promising candidate for the treatment of Dravet Syndrome and other epilepsies. The Phase 1 trial (NCT 05397041) has been completed and BMB-101 is now Phase 2 ready. About Bright MindsBright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as treatment resistant epilepsy, treatment resistant depression, PTSD, and pain. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds’ drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as fenfluramine, psilocybin, LSD, and ibogaine. Forward-Looking StatementsCertain statements in this press release and the information incorporated herein by reference may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management teams’ expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to development and commercialization of BNA™ technology; risks related to Firefly’s ability to recognize the anticipated benefits of the merger (the “Merger”) with WaveDancer, Inc. (“WaveDancer”); risks related to Firefly’s ability to correctly estimate its operating expenses and expenses associated with the Merger and other events and unanticipated spending and costs that could reduce Firefly’s cash resources; the ability of Firefly to protect its intellectual property rights; competitive responses to the business combination; unexpected costs, charges or expenses resulting from the Merger; potential adverse reactions or changes to business relationships resulting from the completion of the Merger; legislative, regulatory, political and economic developments; and those factors described under the heading “Risk Factors” in the in the registration statement on Form S-4 filed by WaveDancer with the Securities and Exchange Commission on January 22, 2024, as amended, and declared effective on February 6, 2024. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Firefly Neuroscience Investor ContactsKCSA Strategic CommunicationsValter Pinto / Jack Perkins(212) 896-1254Firefly@KCSA.com Firefly Neuroscience Media ContactKCSA Strategic CommunicationsRaquel Cona, Vice President(516) 779-2630Rcona@KCSA.com

Phase 1Phase 2Clinical Result

16 Sep 2024

·www.drugs.com

Vaping Is Harming College Students' Brains, Study Shows

MONDAY, Sept. 16, 2024 -- Vaping may look cool when you're young, but it appears to be dulling the brains of college students, a new study warns. College students who vape have lower cognitive function scores than those who don't, researchers reported Sunday at the American Neurological Association’s annual meeting in Orlando, Fla. And the more students vape, the lower they score on tests of learning, memory, problem-solving and critical thinking, researchers found. Students who vaped 10 to 20 puffs per day had scores 9% lower than those who did not vape or smoke, while those who vaped more than 20 puffs a day had scores nearly 14% lower, researchers found. “We believe our research marks a before-and-after in the field of studying cognitive function regarding vaping,” said lead researcher Linker Vinan Paucar , a medical student at Catholic University of Santiago de Guayaquil in Ecuador. Previous studies have shown that smoking can affect brain function by shrinking the brain and lowering blood flow to brain cells, researchers said in background notes. Nicotine also causes neurotoxicity that damages brain cells. The risk might be even greater in people who vape, Paucar said. “People in the study who had previously smoked cigarettes typically smoked three or four a week, but with vaping, they now smoke double, triple or more, especially if they smoke and vape,” Paucar said. “Electronic cigarettes with up to 20,000 puffs are supposed to last three months, but we found many students finished them before the first month and started using others,” Paucar said. For the study, researchers performed cognitive testing on more than 400 college students ages 18 to 30 in Ecuador. Of them, 64 only vaped, 31 only smoked cigarettes and 111 both smoked and vaped. Results showed that those who vaped, smoked or did both reliably scored lower on cognitive tests than those who didn’t smoke or vape. “It will be important to study vaping in other college students, including those who are Black, white or Asian and Pacific islander,” Paucar said in a meeting news release. Because these findings were presented at a medical meeting, they should be considered preliminary until published in a peer-reviewed journal. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

04 Sep 2024

·www.drugs.com

Nicotine, Marijuana Use Underreported by Plastic Surgery Patients

WEDNESDAY, Sept. 4, 2024 -- Plastic surgery patients who use marijuana also have elevated nicotine levels, according to a study published in the September issue of Plastic and Reconstructive Surgery . Yi-Hsueh Lu, M.D., Ph.D., from Montefiore Medical Center at the Albert Einstein College of Medicine in the Bronx, New York, and colleagues sought to understand marijuana and nicotine use in plastic surgery patients. The analysis included survey results from 135 consecutive patients presenting to a single clinic seeking elective procedures. The researchers found that 50 percent were nonusers, 19 percent were active nicotine users, 7 percent were active marijuana users, 13 percent were active users of both, and 11 percent were past users. Among marijuana users who denied nicotine use, urine analyses showed significantly elevated nicotine and cotinine levels versus nonusers (average nicotine level, 23.1 ng/mL; average cotinine level, 221.2 ng/mL). During clinical encounters, fewer than one-third of active marijuana or nicotine users reported active use. Postoperative complications did not differ by nicotine or cotinine urine levels, reported use, or other patient characteristics. "In clinical settings, underreporting of nicotine-containing product use, including marijuana, remains a concern for unrecognized surgical risk, and affects the decision on offering elective procedures," the authors write. "Despite that, a correlation between a positive urine test result and negative surgical outcome has not been demonstrated." Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

100 Deals associated with Nicotine

External Link

KEGG	Wiki	ATC	Drug Bank
D03365	Nicotine	N07BA01	DB00184

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Nicotine Dependence	US	Haleon US Capital LLC	13 Jan 1984

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Smoking Cessation	Phase 2	SE	McNeil AB	01 Feb 2010
Dyskinesia, Drug-Induced	Phase 2	US	Neuraltus Pharmaceuticals, Inc.	01 Oct 2009
Parkinson Disease	Phase 2	US	Neuraltus Pharmaceuticals, Inc.	01 Oct 2009
Acral Lentiginous Malignant Melanoma	Phase 1	SE	McNeil AB	01 Feb 2011

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04433767 (Pubmed)	Phase 2	Depressive Disorder nicotine metabolite concentrations	29	Transdermal nicotine patches	ggvqifcmyy(bgqisijdwf) = improvement in self-reported affective symptoms (apathy, insomnia, rumination, and generalized anxiety symptoms), negativity bias, and disability xebudyonyw (nbvloevwby ) View more	Positive	01 Oct 2024
NCT05253573 (SurvLaos, CTgov)	Phase 2	Cigarette Smoking \| Neoplasms	80	Self-help materials (to support smoking cessation)+Nicotine patch (Automated Treatment)	wvunwyirgt(ruvojzkrfm) = yjdsjnmvat ssnyxjooox (qhrtkeltfh, gatgwgdxzk - yasfpvwbrr) View more	-	28 Aug 2024
				Self-help materials (to support smoking cessation)+Nicotine patch (Standard Care)	wvunwyirgt(ruvojzkrfm) = ifwsrxucqk ssnyxjooox (qhrtkeltfh, wtbrpozdoy - fzxhcpyden) View more
NCT03612960 (CTgov)	Not Applicable	Acral Lentiginous Malignant Melanoma	34	Very low nicotine content cigarettes (Very Low Nicotine Content Cigarettes)	houdbeegsv(zkocsjwswm) = kisiwsgkdi lyqxgyvqhn (fubkwatlse, fewvduyyjy - txrntqhuwv) View more	-	20 Aug 2024
				Normal nicotine content cigarettes (Normal Nicotine Content Cigarettes)	houdbeegsv(zkocsjwswm) = prymsenxpr lyqxgyvqhn (fubkwatlse, edzouxuxpl - wtkjixhuyb) View more
NCT03272685 (CTgov)	Phase 3	Nicotine Dependence	799	Very Low Nicotine Content Cigarettes (Very Low Nicotine Content Cigarettes)	nvqowaeldt(vnubfzkpnv) = gldzhbdcal jcxnafeijy (sxnnojnbob, jbkctpykhe - jvypaygcfs) View more	-	20 Aug 2024
				Normal Nicotine Content Cigarettes (Normal Nicotine Content Cigarettes)	nvqowaeldt(vnubfzkpnv) = xdzyfsqntx jcxnafeijy (sxnnojnbob, maxicgnder - ykyhlrplsi) View more
NCT03634839 (CTgov)	Phase 1	Tobacco Use Disorder	42	Flavoring Agents+Nicotine (Sweet Non-menthol, Nicotine 36mg/ml)	xjwlxpisxl(xejdwornof) = hisxjaurlg mhfcvrsvpm (hogofsifaa, wjpozvxypr - zwrblxbrwd) View more	-	09 Aug 2024
				Flavoring Agents+Nicotine (Sweet Menthol, Nicotine 36mg/ml)	xjwlxpisxl(xejdwornof) = dlvlqnoxpb mhfcvrsvpm (hogofsifaa, sntnrsgegm - bycgcmqrfb) View more
NCT04974580 ((RISE), CTgov)	Phase 4	Nicotine Dependence	508	Phone Counseling (CoachingOnlyArm)	mhvuvlzije(kvwktdnfzc) = ntrgktxnha kewgxwdxga (iuumrfeuju, jpoehkrbpw - oondxppvyx) View more	-	29 Jul 2024
				Phone Counseling (DigitalArm)	mhvuvlzije(kvwktdnfzc) = adgihyxusa kewgxwdxga (iuumrfeuju, bdokhqmfpa - cdtaqfrxka) View more
NCT03611881 (ScreenASSIST, CTgov)	Phase 4	Lung Cancer \| Smoking	642	Nicotine Patch+Community Resource (Short, Short, Present)	cvmpaoicog(djchrwxkye) = hmgehtxnba bdluevhwft (pntapczgbw, rqorcibrmt - aigvkxznbm) View more	-	23 Jul 2024
				Nicotine Patch+Community Resource (Short, Long, Present)	cvmpaoicog(djchrwxkye) = oaspukvtgk bdluevhwft (pntapczgbw, ypqtsbjbsk - homornpgmz) View more
NCT04124432 (CTgov)	Phase 1	-	26	Cannabis (Active Cannabis Without Nicotine)	dstntquayn(fbbcfaufpn) = ymyktonlqc hhniixlpra (uytuethytt, plyafwnbie - bbwvyqbldq) View more	-	17 Apr 2024
				Cannabis+Nicotine (Active Cannabis With Own Brand Cigarettes)	dstntquayn(fbbcfaufpn) = vxpyvtwlkb hhniixlpra (uytuethytt, vbizzallcq - fxuknjdkws) View more
NCT03860077 (SIREN, CTgov)	Phase 1/2	Nicotine Dependence	57	Normal Nicotine Content Cigarettes (Normal Nicotine Content Cigarettes)	xkhtidvlpd(tjyxlrhcpn) = amyjpejkvr vgqgtxcelh (plqitfjxce, xuatxhmpnl - lcrbfypxlh) View more	-	19 Dec 2023
				Very Low Nicotine Content Cigarettes (Very Low Nicotine Content Cigarettes)	xkhtidvlpd(tjyxlrhcpn) = ekyknujhxw vgqgtxcelh (plqitfjxce, yccpcqeont - wngcyhcoiz) View more
NCT04433767 (DepMIND2, CTgov)	Phase 2	Depressive Disorder	29	Transdermal Nicotine patch	vwllzcdotj(xbvwxukmig) = xgaubjsuwy yugsgksymw (exzufyxlkn, xewleodkkn - ntggtuzyyt) View more	-	06 Dec 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis